A landmark in cancer treatment has come full circle, as the U.S. Food and Drug Administration (FDA) approved revumenib, a revolutionary drug for relapsed or refractory acute leukemia with a KMT2A translocation on November 15, 2024. This life-saving therapy, first administered to a Florida Cancer Specialists & Research Institute, LLC (FCS) patient at its Sarasota Drug Development Unit (DDU) in 2019 as part of a Phase 1 clinical trial, is now available to patients nationwide.
The very first patient to ever receive this groundbreaking treatment was referred by FCS medical oncologist/hematologist Muhammad Imam, MD to FCS Director of Drug Development Manish R. Patel, MD at the FCS Sarasota DDU, one of three early-phase clinical trial sites within the statewide practice. This milestone underscores FCS‘ fundamental role in the development of this drug, which has now gained FDA approval for its remarkable ability to target and treat MLL-rearranged leukemia.
